Chemokine has begun a Phase Ib/II trial of its anticancer candidate CTCE-9908.
The trial will enroll up to 30 patients with late-stage cancers, including breast, lung, prostate and ovarian cancer. The company said it expects to file an investigational new drug application with the FDA and expand its clinical program for CTCE-9908.
